Objectives: We evaluated safety and efficacy of dapsone gel 7.5% (DAP) in acne patients by Fitzpatrick skin type. MethOds: Data were pooled from 2 identically designed, phase 3, multicenter, randomized, double-blind studies in patients ≥ 12 years of age with moderate acne. Patients applied DAP or vehicle (VEH) once daily for 12 weeks. Efficacy assessments included Global Acne Assessment Score (GAAS) and lesion counts. Patients self-evaluated acne impact using Acne Symptom and Impact Scale (ASIS). Adverse events (AEs) and dermal tolerability were assessed. Results: In total, 4327 patients (2216 type I-III, 2111 type IV-VI) were included. At week 12, mean GAAS change from baseline was significantly greater with DAP versus VEH in skin types I-III and IV-VI (both, P< 0.001). Additionally, 71.4% with types I-III and 76.6% with types IV-VI using DAP achieved ≥ 1-grade improvement in GAAS at week 12 versus 62.8% and 67.9% using VEH (P< 0.001). In types I-III and IV-VI, mean week 12 percent reductions were significantly greater for DAP versus VEH in inflammatory lesions (types I-III, P< 0.001; IV-VI, P= 0.002), comedones (types I-III, P< 0.001; IV-VI, P= 0.01), and total lesions (both, P< 0.001). For both skin type groups, inflammatory lesion improvements occurred first; similar improvement patterns occurred in GAAS, comedones, and ASIS domains. Local dermal tolerability and AE incidences were similar between skin type groups and between DAP and VEH. cOnclusiOns: Once-daily DAP monotherapy was safe and effective in lighter and darker Fitzpatrick skin type patients with moderate acne.Objectives: Sentinel surveillance in Peru reports 29,132 outpatient (average 2009-14) and 9,124 hospitalized (2016) varicella cases, likely an underestimate of true burden. The objective of this study was to quantify the burden of varicella in Peru, and estimate potential impact and cost-effectiveness of universal varicella vaccination (UVV). MethOds: A dynamic transmission model of varicella infection was calibrated to reported age-specific varicella incidence data, adjusted for underreporting and care-seeking patterns. Results from a recent chart review study provided data on unit costs and health-care resource utilization. Vaccination strategies based on the current Peruvian vaccination calendar and coverage were considered (A: 1st dose 12m/90% coverage; B: 1st dose 18m/60%; C: 1st dose 12m/90% + 2nd dose 18m/60%; D: 1st dose 12m/90% + 2nddose 4y/50%). Scenario analyses focused on varicella vaccine qualities (effectiveness, duration) and costs. Results: More than 500,000 varicella cases per year at a cost of over S/50M (Peruvian S/1= 0.31USD) were estimated, and all vaccination strategies were cost-saving (payer perspective). The most cost-effective strategy for a vaccine with long duration of protection was D, followed by C, A, and B, but for vaccines with shorter duration of protection C was preferred to D. Notably, two-dose strategies based on high-quality vaccines, even at higher prices, were more effective and cost-effective than stra...